HK Stock Market Move | XPENG-W (09868) opens up nearly 3%, expected to mass produce the second generation VLA with L4 level capability in the first quarter of next year.
Xiaopeng Motors (09868) opened nearly 3% higher, and as of the time of writing, rose by 2.53% to 73 Hong Kong dollars, with a turnover of 420.48 million Hong Kong dollars.
XPENG-W(09868) opened nearly 3% higher, as of the time of writing, it rose 2.53% to 73 Hong Kong dollars with a trading volume of 4.2048 million Hong Kong dollars.
On the news front, recently, according to First Finance, Xiaopeng Motors has obtained an L3-level automatic driving road test license in Guangzhou and has started standardized L3 road testing. The license is mainly used for conditional automatic driving tests on high-speed roads for intelligent connected vehicles in Guangzhou. Changjiang pointed out that Xiaopeng Motors continues to lead in the field of intelligent driving relying on its integrated advantages in software and hardware. With the on-board self-developed Turing chip and the advancement of large-scale cloud-based models, intelligent driving has entered the second generation VLA stage. The company expects to mass produce the second generation VLA with L4 level capabilities in the first quarter of 2026, and expects to launch Robotaxi models with L4 capabilities in 2026.
The bank further pointed out that Xiaopeng Motors has fully shifted its focus to an AI strategy, positioning itself as a global AI automotive company, and clearly stating that it will transform into an AI automotive intelligent technology enterprise in the next ten years. The company has built a "Trinity" embodied intelligent ecological layout, covering AI vehicles, AISiasun Robot&Automation, and flying cars. Among them, the "aircraft carrier" for flying cars has accumulated orders for 7,000 units, the flying car intelligent manufacturing base has been completed, and it has the "annual production capacity of tens of thousands of vehicles."
Related Articles

CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.






